New drug combo shows promise for Hard-to-Treat breast cancer
NCT ID NCT03620643
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This study tested a combination of two drugs, crizotinib and fulvestrant, in 33 people with advanced lobular breast cancer or other cancers linked to a CDH1 gene mutation. The goal was to see if the treatment could shrink tumors and to check for side effects. While both drugs had been studied before, this was the first time they were used together.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
-
Guys and St Thomas NHS Foundation Trust
London, United Kingdom
-
Royal Marsden NHS Foundation Trust
London, SW3 6JJ, United Kingdom
-
The Christie NHS Foundation Trust
Manchester, United Kingdom
-
University College London Hospital
London, United Kingdom
Conditions
Explore the condition pages connected to this study.